Recent Developments

Celtic Pharma Reports Data Presented at Society for Neuro-Oncology Annual Meeting and Provides Update on XERECEPT® Clinical Program

December 4, 2007
Celtic Pharma today reported interim study results for XERECEPT® (human corticotropin-releasing factor (hCRF)), which were presented at the 12th Annual Meeting of the Society for Neuro-Oncology ("SNO"), and provided an update on the XERECEPT® clinical development program.
Read the full press release

Celtic Pharma completes rapid enrollment in Phase IIB study for TA-NIC, the nicotine vaccine for smoking cessation

October 29, 2007
Celtic Pharma announces it has completed enrollment in a large Phase IIB clinical study in the US. Over 520 patients were recruited into the study in 10 weeks, significantly ahead of schedule.
Read the full press release

Celtic Pharma Announces Initiation of Phase II Clinical Trial for TDT-067, a Treatment for Onychomycosis

October 15, 2007
Celtic Pharma announced today the enrollment of the first patient into the Phase II trial of TDT-067, terbinafine in Transfersomes®, for the treatment of onychomycosis. This is an open-label study to explore the efficacy and safety of topically applied terbinafine delivered through the Transfersome® targeted delivery technology. Celtic Pharma acquired an exclusive global licence to IDEA AG’s Transfersome® technology in February 2006.
Read the full press release

Celtic Pharma portfolio company, IDEA AG, signs major licensing agreement with Alpharma Inc.

September 6, 2007
Celtic Pharmaceutical Holdings L.P. announces that its German portfolio company, IDEA AG has licensed the US rights to its lead product, Diractin® for the treatment of deep pain, to an affiliate of Alpharma Inc. a specialty pharmaceutical company, whose shares are listed on the New York Stock Exchange. Diractin® is a transdermal formulation of ketoprofen which utilizes IDEA’s innovative Transfersome® targeted drug delivery platform.
Read the full press release

Celtic Pharma and Neurobiological Technologies report updated results from long-term open-label extension study for Xerecept, and its clinical development status

June 5, 2007
Celtic Pharma and Neurobiological Technologies, Inc. (NTII) announced today the results of an updated ongoing report on the Xerecept 501 open-label Phase III study, as presented at the annual meeting of the American Society of Clinical Oncology. Peritumoral edema patients who have participated in one of the two Phase III, double-blinded, placebo controlled studies currently underway to assess Xerecept’s dexamethasone-sparing potential are given the option of enrolling in the 501 study. To date a total of 65 patients have enrolled in the 501 study, including 11 patients who have now been on Xerecept therapy for more than one year.
Read the full press release

Celtic Pharma receives IND approval to initiate a large randomized study in the US for TA-NIC, its immunotherapy vaccine for the treatment of smoking cessation.

April 30, 2007
Celtic Pharmaceuticals Holdings L.P. ("Celtic Pharma") today announced it has received IND approval for TA-NIC, a vaccine being developed for the treatment of nicotine addiction. TA-NIC is designed to induce nicotine-specific antibodies. When nicotine enters the bloodstream of a TA-NIC-dosed patient it will encounter and bind to these antibodies. The antibody-nicotine complex is too large to cross the blood-brain barrier, so the pleasurable stimulus which typically accompanies smoking should be absent or reduced. The prior owners of TA-NIC completed two phase I/II studies in the United Kingdom in 120 patients who were smokers. These vaccination studies were not associated with any unexpected adverse events and there were indications of efficacy in the treated group compared to placebo.
Read the full press release

Celtic Pharmaceutical Holdings L.P. Raises $156 Million in Debt, Bringing Total Capital to over $400 Million

February 7, 2007
Celtic Pharma announced today that its finance subsidiary, Celtic Pharma Cooperatieve W.A., has closed a $156 million private placement of notes. Celtic Pharma closed in 2006 with approximately $250 million in limited partner subscriptions, and has also completed four significant transactions.
Read the full press release

Celtic Pharma Terminates Transmid™ Trial Ksb311R/Ciii/001

February 7, 2007
Celtic Pharma announced today the termination of trial KSB311R/CIII/001 of its investigational new drug TransMID™.
Read the full press release

Celtic Pharma appoints two new senior executives.

November 21, 2006
Celtic Pharma Development Services Bermuda Ltd. (“CPDS”) has appointed Bob Milsted as Managing Director and Head of European Development and Solomon Babani as Director of Contracts and Vendor Management.
Read the full press release

XERECEPT® Update Presented at Society for Neuro-Oncology Meeting.

November 17, 2006
Celtic Pharma and Neurobiological Technologies Present an Update on XERECEPT® for Peritumoral Brain Edema at the 11th Annual Meeting of the Society For Neuro-Oncology.
Read the full press release

Celtic Pharma Notes Progress By IDEA AG

August 2, 2006
Successful completion of second European Phase III pivotal trial for IDEA-033, the targeted pain-killer for osteoarthritis. Reacquisition of North American rights by IDEA provides global asset with blockbuster potential.
Read the full press release

Celtic Pharma Reports Preliminary Results Of Phase 2 Clinical Trials With TA-CD, Cocaine Addiction Vaccine

June 21, 2006
Preliminary results from two Phase 2 studies of TA-CD, a novel immunotherapy vaccine for the treatment of cocaine addiction, sponsored by the National Institute on Drug Abuse (“NIDA”), were presented on June 16, 2006, and reviewed at a meeting in Scottsdale, AZ, of NIDA officials, a panel of drug addiction experts from leading US research institutions and the Celtic Pharma team.
Read the full press release